FDA Flags High-Risk Issue with Erbe Flexible Cryoprobes

The FDA’s Center for Devices and Radiological Health (CDRH) has issued an Early Alert regarding a potentially high-risk issue involving certain flexible cryoprobes manufactured by Erbe USA.

Issue Overview

Erbe USA has identified a defect in specific cryoprobe models that may cause the device to rupture or burst during activation. The root cause of the issue is insufficient adhesive applied during manufacturing, resulting in excessive internal pressure leading to device failure

Risk to Patients and Users

A device rupture may result in a loud explosive sound, tinnitus or hearing loss (temporary or permanent) and burns or physical injury to patients or healthcare personnel.

As of February 24, five serious injuries were reported and no deaths were reported.

Required Actions (Immediate)

The FDA and manufacturer are advising all users to immediately discontinue use of affected devices, identify and quarantine impacted lot numbers, notify all relevant personnel and downstream users, and ensure redistributed products are tracked and recalled

Device Context

Flexible cryoprobes are used in interventional procedures for tissue destruction (cryotherapy), removal of foreign bodies, clots, and mucus plugs, tumor debulking, and biopsy support.

Given their use in critical airway and tissue procedures, device integrity is essential.

Regulatory Status

This is an FDA Early Alert, indicating a potentially high-risk issue under active review. Additional updates may follow as more data becomes available.

MDP Insight: What This Means for Manufacturers and Providers

This alert highlights several important regulatory and quality considerations.

Manufacturing Controls Matter

A seemingly minor issue, adhesive application, resulted in a high-risk device failure mode. This reinforces the importance of process validation, supplier/material controls, and production consistency.

Risk Management Must Address Use Conditions

Devices used under pressure or extreme conditions require robust design controls that include a failure mode analysis.

Field Action Execution Is Critical

Effective recall/notification processes must ensure rapid identification of affected lots, clear communication across distribution chains, and user awareness at the point of care.

Bottom Line

This event underscores how manufacturing variability can translate directly into patient risk, particularly in interventional devices. For manufacturers, it is a reminder that small process deviations can have large clinical consequences, and postmarket surveillance and rapid response systems are essential.

Download a list of recalled product lot numbers

Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor

On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...

Eugia Vancomycin Recall: Glass Particle Contamination

FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...

FDA Requires New GLP-1 Drug Warning for Vision Loss Risk

Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...

When Political Priorities and FDA Science Collide

HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...

What to Know about FDA’s Revised Peptide Guidance

What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...

The Regulatory Dilemma of Experimental Peptides

As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...